Psychedelic News and Analysis Made Simple for Investors
Psychedelic Invest is a resource for those looking to invest in the burgeoning psychedelic industry.
Track the entire psychedelic market
We’ve developed the first all encompassing index to track the public psychedelic marketplace.
Explore the Index
Just Some of the Data we Cover
Latest News
Press
Apr 3
•
2 min read
Vancouver, British Columbia – TheNewswire – April 2, 2025 – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6), (the “Company” or “MindBio”), a clinical stage biopharmaceutical company pioneering new treatments for mental health conditions announces that it has adopted a new equity incentive plan (the “New Plan”). The New Plan is a 20% rolling equity incentive plan that provides for the issuance…
Press
TORONTO, April 01, 2025 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases, rare disorders, and medical countermeasures, is pleased to announce that further to its press release dated March 3, 2025, it…
Apr 3
•
4 min read
Press
Vancouver, Canada, April 01, 2025 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced today the launch of its Electronic Data Capture (EDC) system to support its Phase I/II clinical trial of its MEAI-based…
Apr 3
•
3 min read
Press
New York, New York–(Newsfile Corp. – March 31, 2025) – Psyence Biomedical Ltd. (NASDAQ: PBM) (“Psyence BioMed” or the “Company”) releases the following update: Dear Shareholders and Future Investors: At Psyence BioMed, we are truly grateful for the ongoing support and trust of our shareholders. Your dedication to our vision drives our growth, and we’re…
Apr 3
•
8 min read
Press
VANCOUVER, BC, April 1, 2025 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company”), a clinical-stage natural psychedelic drug development company, released its fourth quarter financial results and operational highlights for the period ended December 31, 2024. “Over the course of 2024, we continued to expand Filament’s position as a leading global supplier of…
Apr 3
•
3 min read
Press
Toronto, Ontario–(Newsfile Corp. – March 31, 2025) – Neural Therapeutics Inc. (CSE: NURL) (FSE: M6B) (“Neural“or the “Company“), an ethnobotanical drug discovery company dedicated to developing therapeutic drugs for mental illnesses related to substance use disorders, is pleased to announce that shares of the company have commenced trading on the Frankfurt Stock Exchange under ticker…
Apr 3
•
2 min read
Press
Vancouver, British Columbia – TheNewswire – March 26, 2025 – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6), (the “Company” or “MindBio”), a clinical stage biopharmaceutical company specialising in psychedelic microdosing, is pleased to announce the completion of its acquisition of all of the outstanding share capital of Life AI Corp. Pty. Ltd. (“Life AI”) pursuant to a definitive share purchase agreement…
Apr 3
•
4 min read
Explore the Psychedelic Landscape
Learn more about the psychedelic companies changing the industry.